HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO CARsgen Therapeutics - Insights on Pipeline and Challenges

Pre-IPO Beijing Keya Medical Technology - Here Are the Strength and the Concerns

Pre-IPO Guangzhou Pharmaceuticals - The Risk Points Gradually Emerged

Pre-IPO Zhaoke Ophthalmology Pharmaceutical - It Remains to Be Seen How to Find Its Way Out

Pre-IPO We Doctor Holdings - Here Are the Concerns

Pre-IPO Shanghai HeartCare Medical Technology - Promising Market but Fierce Competition

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

On February 24th, 2021, <a href="https://www.smartkarma.com/entities/yishengbio-co-ltd" target="_blank" data-smartkarma-citation="entities:32205:1" rel="noopener">YishengBio (1872307D HK)</a> announced the completion of a Series B financing of over $130 million, led by Oceanpine and OrbiMed. Soon after, on March 8th, Yisheng filed its IPO prospectus with the HKEX. Since the Changchun Changsheng vaccine scandal in 2018, rabies vaccines have been in short supply in China. Therefore, vaccine companies hope to seize this opportunity and develop vigorously with the help of the capital market. For example, last year, <a href="https://www.smartkarma.com/entities/chengdu-kanghua-biological-a" target="_blank" data-smartkarma-citation="entities:29895:1" rel="noopener">Chengdu Kanghua Biological-A (300841 CH)</a> was listed on the A-share market successfully. This year, Yisheng also plans to raise funds, expand the business and fund the future operation in the public capital market.

On February 24th, 2021, YishengBio (1872307D HK) announced the completion of a Series B financing of over $130 million, led by Oceanpine and OrbiMed. Soon after, on March 8th, Yisheng filed its IPO prospectus with the HKEX. Since the Changchun Changsheng vaccine scandal in 2018, rabies vaccines have been in short supply in China. Therefore, vaccine companies hope to seize this opportunity and develop vigorously with the help of the capital market. For example, last year, Chengdu Kanghua Biological-A (300841 CH) was listed on the A-share market successfully. This year, Yisheng also plans to raise funds, expand the business and fund the future operation in the public capital market. 

Chongqing Zhifei Biological Products (300122 CH)

Shenzhen Kangtai Biological Pr (300601 CH)

Chengdu Kanghua Biological Pro (300841 CH)

Pre-IPO YishengBio Co., Ltd  - Here Are the Concerns Despite Solid Market Potential